Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chemotherapy of non-small cell lung cancer.

Literature DB >> 2553089

Chemotherapy of non-small cell lung cancer.

C J Williams¹.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 1989 PMID： 2553089 PMCID： PMC2247340 DOI： 10.1038/bjc.1989.209

Source DB: PubMed Journal: Br J Cancer ISSN： 0007-0920 Impact factor: 7.640

× No keyword cloud information.

11 in total

1. Bronchial carcinoma treated by adjuvant cancer chemotherapy.

Authors: T W Shields; C D Robinette; R J Keehn
Journal: Arch Surg Date: 1974-08

2. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.

Authors: T W Shields; G A Higgins; E W Humphrey; M J Matthews; R J Keehn
Journal: Cancer Date: 1982-11-01 Impact factor: 6.860

3. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design.

Authors: P Van Houtte; P Rocmans; P Smets; J C Goffin; J Lustman-Maréchal; P Vanderhoeft; J Henry
Journal: Int J Radiat Oncol Biol Phys Date: 1980-08 Impact factor: 7.038

4. Risk-benefit relationships in cancer clinical trials: the ECOG experience in non-small-cell lung cancer.

Authors: R J Simes
Journal: J Clin Oncol Date: 1985-04 Impact factor: 44.544

5. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.

Authors: E C Holmes; M Gail
Journal: J Clin Oncol Date: 1986-05 Impact factor: 44.544

6. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

Authors: E Rapp; J L Pater; A Willan; Y Cormier; N Murray; W K Evans; D I Hodson; D A Clark; R Feld; A M Arnold
Journal: J Clin Oncol Date: 1988-04 Impact factor: 44.544

7. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group.

Authors:
Journal: J Clin Oncol Date: 1988-01 Impact factor: 44.544

8. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

Authors: R J Gralla; E S Casper; D P Kelsen; D W Braun; M E Dukeman; N Martini; C W Young; R B Golbey
Journal: Ann Intern Med Date: 1981-10 Impact factor: 25.391

Chemotherapy of non-small cell lung cancer.

1. Bronchial carcinoma treated by adjuvant cancer chemotherapy.

2. Prolonged intermittent adjuvant chemotherapy with CCNU and hydroxyurea after resection of carcinoma of the lung.

3. Postoperative radiation therapy in lung caner: a controlled trial after resection of curative design.

4. Risk-benefit relationships in cancer clinical trials: the ECOG experience in non-small-cell lung cancer.

5. Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma.

6. Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.

7. The benefit of adjuvant treatment for resected locally advanced non-small-cell lung cancer. The Lung Cancer Study Group.

8. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules.

9. Mitomycin, ifosfamide and cis-platin in non-small cell lung cancer: treatment good enough to compare.

10. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer.

1. P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cells in vivo.

2. Expression of the multidrug resistance-associated protein (MRP) gene in non-small-cell lung cancer.